← 홈

림프종

587개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 587개
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma · B-Cell Neoplasm

#B-CellNeoplasm#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 10상태 RECRUITING
ADCBiologicstaleThe Thai Lymphoma Study GroupPhase 2

B-MAD chemotherapy (B-MAD chemotherapy)

Extranodal NK/T-cell Lymphoma · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 9상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 2

CHEP (CHEP)

Lymphoma; Adult T-Cell Leukemia/Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 2%임상시험 9상태 RECRUITING
CGTBiologicstaleKitePhase 2

Tecartus (Tecartus)

Acute Lymphoblastic Leukemia; Large B-cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 86%임상시험 9상태 RECRUITING
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab Vedotin, Rituximab (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab vedotin and Rituximab (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Talazoparib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 0%임상시험 8상태 RECRUITING
ADCBiologicstaleMedImmune LLCPhase 1

BL22 immunotoxin (BL22 immunotoxin)

Leukemia; Lymphoma · Leukemia

#Leukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 0%임상시험 8상태 ACTIVE
ADCBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (MB-CART2019.1)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 8상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 2

PI3K-beta Inhibitor GSK2636771 (PI3K-beta Inhibitor GSK2636771)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 9%임상시험 8상태 RECRUITING
AntibodystaleInnoventPhase 2

Sintilimab+Pegaspargase (Sintilimab+Pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Phase2#항체#면역항체+5
임상시험 8상태 RECRUITING
CGTBiologicstaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 7상태 RECRUITING
CGTBiologicstaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 77.3%임상시험 7상태 RECRUITING
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART19.1 (MB-CART19.1)

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory · Melanoma Stage III

#MelanomaStageIII#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 7상태 ACTIVE
CGTBiologicstaleStephan Grupp MD PhDPhase 2

CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD22

#CD22#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 6상태 RECRUITING
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

Central Nervous System Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
효능 ORR 9.9%임상시험 6상태 DISCONTINUED
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE

9 / 30 페이지

← 이전다음 →